Insomnia és cerebralis hypoperfusio

Translated title of the contribution: Insomnia and cerebral hypoperfusion

Z. Káposzta, Klára Rácz

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Insomnia is defined as difficulty with the initiation, maintenance, duration, or quality of sleep that results in the impairment of daytime functioning, despite adequate opportunity and circumstances for sleep. In most countries approximately every third inhabitant has insomnia. Insomnia can be classified as primary and secondary. The pathogenesis of primary insomnia is unknown, but available evidence suggests a state of hyperarousal. Insomnia secondary to other causes is more common than primary insomnia. Cerebral hypoperfusion can be the cause of insomnia in some cases. In such patients the cerebral blood flow should be improved using parenteral vascular therapy. If insomnia persists despite treatment, then therapy for primary insomnia should be instituted using benzodiapine-receptor agonists such as Zolpidem, Zopiclone, or Zaleplon. In those cases Midazolam cannot be used for the treatment of insomnia due to its marked negative effect on cerebral blood flow. In Hungary there is a need to organize multidisciplinary Insomnia Clinics because insomnia is more than a disease, it is a public health problem in this century.

Original languageHungarian
Pages (from-to)2163-2166
Number of pages4
JournalOrvosi Hetilap
Volume148
Issue number46
DOIs
Publication statusPublished - Nov 18 2007

Fingerprint

Sleep Initiation and Maintenance Disorders
Cerebrovascular Circulation
zopiclone
zaleplon
Sleep
Hungary
Midazolam
Therapeutics
Blood Vessels
Public Health
Maintenance

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Insomnia és cerebralis hypoperfusio. / Káposzta, Z.; Rácz, Klára.

In: Orvosi Hetilap, Vol. 148, No. 46, 18.11.2007, p. 2163-2166.

Research output: Contribution to journalArticle

Káposzta, Z. ; Rácz, Klára. / Insomnia és cerebralis hypoperfusio. In: Orvosi Hetilap. 2007 ; Vol. 148, No. 46. pp. 2163-2166.
@article{203f3c721e424d18adfd3afb1a6056f3,
title = "Insomnia {\'e}s cerebralis hypoperfusio",
abstract = "Insomnia is defined as difficulty with the initiation, maintenance, duration, or quality of sleep that results in the impairment of daytime functioning, despite adequate opportunity and circumstances for sleep. In most countries approximately every third inhabitant has insomnia. Insomnia can be classified as primary and secondary. The pathogenesis of primary insomnia is unknown, but available evidence suggests a state of hyperarousal. Insomnia secondary to other causes is more common than primary insomnia. Cerebral hypoperfusion can be the cause of insomnia in some cases. In such patients the cerebral blood flow should be improved using parenteral vascular therapy. If insomnia persists despite treatment, then therapy for primary insomnia should be instituted using benzodiapine-receptor agonists such as Zolpidem, Zopiclone, or Zaleplon. In those cases Midazolam cannot be used for the treatment of insomnia due to its marked negative effect on cerebral blood flow. In Hungary there is a need to organize multidisciplinary Insomnia Clinics because insomnia is more than a disease, it is a public health problem in this century.",
keywords = "Hypoperfusion, Insomnia, Sleep, Stroke",
author = "Z. K{\'a}poszta and Kl{\'a}ra R{\'a}cz",
year = "2007",
month = "11",
day = "18",
doi = "10.1556/OH.2007.28232",
language = "Hungarian",
volume = "148",
pages = "2163--2166",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "46",

}

TY - JOUR

T1 - Insomnia és cerebralis hypoperfusio

AU - Káposzta, Z.

AU - Rácz, Klára

PY - 2007/11/18

Y1 - 2007/11/18

N2 - Insomnia is defined as difficulty with the initiation, maintenance, duration, or quality of sleep that results in the impairment of daytime functioning, despite adequate opportunity and circumstances for sleep. In most countries approximately every third inhabitant has insomnia. Insomnia can be classified as primary and secondary. The pathogenesis of primary insomnia is unknown, but available evidence suggests a state of hyperarousal. Insomnia secondary to other causes is more common than primary insomnia. Cerebral hypoperfusion can be the cause of insomnia in some cases. In such patients the cerebral blood flow should be improved using parenteral vascular therapy. If insomnia persists despite treatment, then therapy for primary insomnia should be instituted using benzodiapine-receptor agonists such as Zolpidem, Zopiclone, or Zaleplon. In those cases Midazolam cannot be used for the treatment of insomnia due to its marked negative effect on cerebral blood flow. In Hungary there is a need to organize multidisciplinary Insomnia Clinics because insomnia is more than a disease, it is a public health problem in this century.

AB - Insomnia is defined as difficulty with the initiation, maintenance, duration, or quality of sleep that results in the impairment of daytime functioning, despite adequate opportunity and circumstances for sleep. In most countries approximately every third inhabitant has insomnia. Insomnia can be classified as primary and secondary. The pathogenesis of primary insomnia is unknown, but available evidence suggests a state of hyperarousal. Insomnia secondary to other causes is more common than primary insomnia. Cerebral hypoperfusion can be the cause of insomnia in some cases. In such patients the cerebral blood flow should be improved using parenteral vascular therapy. If insomnia persists despite treatment, then therapy for primary insomnia should be instituted using benzodiapine-receptor agonists such as Zolpidem, Zopiclone, or Zaleplon. In those cases Midazolam cannot be used for the treatment of insomnia due to its marked negative effect on cerebral blood flow. In Hungary there is a need to organize multidisciplinary Insomnia Clinics because insomnia is more than a disease, it is a public health problem in this century.

KW - Hypoperfusion

KW - Insomnia

KW - Sleep

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=36749072213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749072213&partnerID=8YFLogxK

U2 - 10.1556/OH.2007.28232

DO - 10.1556/OH.2007.28232

M3 - Article

VL - 148

SP - 2163

EP - 2166

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 46

ER -